Reach Us +44-1904-929220
ANXA7 Expression has Prognostic Impact for Patient Survival In Triple Negative Breast Cancers | OMICS International | Abstract

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

ANXA7 Expression has Prognostic Impact for Patient Survival In Triple Negative Breast Cancers

Meera Srivastava1*, Ofer Eidelman1, Lukas Bubendorf2 and Harvey B. Pollard1

1Department of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University School of Medicine (USUHS), Bethesda, MD.20814

2Institute for Pathology, University of Basel, Switzerland

*Corresponding Author:
Meera Srivastava, Ph.D
Department of Anatomy and Cell Biology
USU School of Medicine,4301 Jones Bridge Road
Bethesda MD, 20814
Tel : 301-295-3204
Fax: 301-295-1786
E-mail: [email protected]

Received Date: June 24, 2011; Accepted Date: July 26, 2011; Published Date: July 28, 2011

Citation: Srivastava M, Eidelman O, Bubendorf L, Pollard HB (2011) ANXA7 Expression has Prognostic Impact for Patient Survival In Triple Negative Negative Breast Cancers. J Mol Biomark Diagn 2:110 doi:10.4172/2155-9929.1000110

Copyright: © 2011 Srivastava M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited


Triple-negative breast cancers account for 10-17% of all breast carcinomas and there is considerable need for reliable prognostic markers to assist clinicians in making diagnostic and therapeutic management decisions. Altered ANXA7 (a novel pro-apoptotic tumor suppressor gene located on chromosome 10q21) protein levels are associated with a tumor-prone phenotype in knockout mouse model and prognostically challenging aggressive forms of prostate and breast cancer. So far, information is not available regarding the association of patient survival and ANXA7 expression in triple-negative breast cancers. Therefore, we used a retrospective prognostic tumor tissue microarray (TMA) technology in order to evaluate the ANXA7 immunoreactivity as a possible diagnostic and/ or prognostic marker of triple-negative breast cancer by immunoperoxidase assay using an ANXA7 monoclonal antibody. We report here that the expression of ANXA7 is significantly enhanced in triple-negative breast cancers and is associated with poor overall patient survival. We conclude that ANXA7 may be a new prognostic markers or a target for improving the treatment efficiency of patients with triple-negative breast cancers.


Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page